This article examines the need to conduct medtech clinical trials outside the U.S. and explores the growth of these trials in Latin America, particularly in Colombia and Paraguay. I will address critical success factors and provide recommendations to ensure cost-effective, ethical, and quality EFS and FIH medtech clinical trials in the region.
Read MoreThis article discusses the 101-year history of vaccine research in Latin America, how Latin America could help solve the vaccine clinical trial diversity problem in the U.S., and why the region is a desirable destination for such clinical research.
Read MoreThis article examines the need to conduct clinical trials outside the U.S. (OUS), addresses the recruitment crisis in the U.S., reviews the incentives for clinical trials overseas, and explores the growth of clinical trials in Latin America. We will profile Colombia as an example of a country committed to attracting more foreign investment in clinical trials.
Read MoreLibella Gene Therapeutics —a US-based company— recently chose Colombia to conduct a phase I clinical trial that could represent a breakthrough in the treatment of Alzheimer's disease (AD) using gene therapy. The approval of a gene therapy trial in Colombia takes 30-45 days from the date of submission to an ethics committee. This time may be shorter or longer depending on how fast the ethics committee at the health institution (aka research center) evaluates the study documents. This positions Colombia as one of the countries with the fastest approval time (and lowest cost) in Latin America for gene therapy research.
Read More
